Home / Renvela Sevelamer Carbonate Tablets For Nephritis
  • Renvela Sevelamer Carbonate Tablets For Nephritis
  • Renvela Sevelamer Carbonate Tablets For Nephritis
  • Renvela Sevelamer Carbonate Tablets For Nephritis
  • Renvela Sevelamer Carbonate Tablets For Nephritis

Renvela Sevelamer Carbonate Tablets For Nephritis

Quantity
ADD TO CART
BUY IT NOW
Detail
Customer Reviews

碳酸司维拉姆片

Generic name: sevelamer carbonate tablets
Chinese Pinyin: TanSuanSiWeiLaMuPian
English name: Sevelamer Carbonate Tablets
Product name: Noval
Ingredients: Sevelamer carbonate.
Functions and indications: Used to control blood phosphorus in patients with chronic kidney disease.
Specification: 800mg*30s
Usage and dosage: The recommended dosage is 3 times a day, 0.8g or 1.6g each time.
Adverse reactions: The adverse reactions of Novila are similar to other azole drugs. The most common treatment-related serious adverse reactions are bilirubinemia, elevated transaminases, liver cell damage, and nausea and vomiting.
Contraindications: People who are allergic to Novila should not be used.
Note: Follow the doctor's advice.
Drug interactions: Drug interactions may occur if used with other drugs at the same time. Please consult your physician or pharmacist for details.
Pharmacology and Toxicology: Sevelamer carbonate is a polymer that cannot be absorbed by the human body and does not contain metal and calcium. It carries multiple amine groups and is connected to the polymer backbone by a carbon atom. These amine groups will be partially protonated in the intestines and combine with phosphoric acid molecules through ion exchange and hydrogen bonding. Sevelamer carbonate reduces the absorption of phosphorus in the gastrointestinal tract and reduces the blood phosphorus concentration.
Pharmacokinetics: The drug is difficult to dissolve in water. At present, it is only an oral suspension. It can be taken orally on an empty stomach or after a meal. The peak plasma concentration is reached in 3~4h and 4~10h respectively. The plasma protein binding rate is as high as 98.2%, which is mainly combined with albumin. The apparent volume of distribution is as high as 1744L on average, with high tissue penetration. It can penetrate the placental barrier and is secreted in milk.
Medication for pregnant women and breastfeeding women: Not yet clear
Children's medication: Not yet clear
Medication for elderly patients: Unclear
Overdose: Unclear
Storage: sealed, kept in a cool and dry place.
Packaging: 800mg*30s/bottle.
Validity period: 18 months
Approval number: H20130662
Company Name: Genzyme Europe B.V.